Ultrasound-Assisted Liposuction and Helium-Activated Radiofrequency Skin Tightening for Treatment of Paradoxical Adipose Hyperplasia After Cryolipolysis

ITEM TYPE:

Journal Article

AUTHORS:

Arian Mowlavi, MD, FACS, Jason Ferrell, BS, Armin Talle, BS, Mariam Berri, BS, and Grant Hamlet, MB, ChB

SUMMARY:

Paradoxical adipose hyperplasia (PAH) following cryolipolysis is a rare but deforming complication. This likely underreported adverse event has been described as being refractory to both traditional tumescent liposuction and repeated cryolipolysis treatments. Here, we present 3 isolated cases with PAH deformity created by cryolipolysis. Management of PAH on the abdomen and flanks involved 2 key elements: ultrasound-assisted liposuction (UAL) technology and helium-activated radiofrequency (RF) energy subdermal coagulation. We observed complete resolution and definitive correction of PAH deformities at 2 weeks, 1 month, and 3 months postoperatively. UAL combined with helium-activated RF subdermal coagulation is a viable surgical modality to correct contour irregularities seen in PAH following cryolipolysis.

APYX® MEDICAL DISCLOSURES:

FINANCIAL DISCLOSURES
This Case Report that is the subject of this journal article authored by Arian Mowlavi, MD, FACS, Jason Ferrell, BS, Armin Talle, BS, Mariam Berri, BS, and Grant Hamlet, MB, ChB was sponsored and funded in part by Apyx Medical through an investigator initiated study grant. Dr. Mowlavi is a paid trainer for Apyx Medical. The other authors declare no conflicts of interest with Apyx Medical in regard to the research, authorship, or publication of this article.

CLEARED INDICATIONS & MANUFACTURING DISCLOSURES

  • Apyx Medical wants to present you with current scientific discourse. Specific usage outside of the general cleared indication may not be safe or effective. Renuvion®/J-Plasma® has received a general clearance and has not been determined to be safe or effective for use in any specific indication or anatomical location.
  • The use of the terms “skin tightening” and “body contouring” in relation to the use of the Renuvion technology has not been approved or cleared by the FDA.
  • Apyx Medical manufactures and owns the Renuvion/J-Plasma technology discussed in this article.

RISKS
Risk associated with the use of the Renuvion technology may include unintended burns (deep or superficial), pneumothorax, scars, temporary or permanent nerve injury, pain, discomfort, gas buildup resulting in temporary and transient crepitus or pain, infection, hematoma, seroma; asymmetry and/or unacceptable cosmetic result. There may be additional risks associated with the use of other devices along with Renuvion and there may be an increased risk for patients who have undergone prior surgical or aesthetic procedures in the treatment area. As with any procedure, individual results may vary. As with all energy devices there are inherent risks associated with its use, refer to the IFU for further information.

INTENDED USE DISCLOSURE
TThe Renuvion system (Apyx Plasma/RF Handpieces) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. The APR HP is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Refer to the Instructions for Use for the currently approved or cleared indications.

0